Case Report: Early Breast Cancer Recurrence Mimicking BIA-ALCL in a Patient With Multiple Breast Procedures

Abstract

Breast reconstruction plays a fundamental role in the therapeutic process of breast cancer treatment and breast implants represents the leading breast reconstruction strategy. Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL), locoregional recurrence in the skin flap, and skin flap necrosis are well-known complications following mastectomy and immediate breast reconstruction (IBR). We report a case of locoregional cancer recurrence in the mastectomy flap mimicking BIA-ALCL, in a patient who underwent 6 breast procedures in four facilities across 15 years including immediate breast reconstruction with macrotextured breast implants. Despite the rate and onset of the disease, clinicians should be aware of BIA-ALCL. Due to the risk of false negative results of fine needle aspiration, clinical suspicion of BIA-ALCL should drive clinicians' choices, aside from cytological results. In the present case, surgical capsulectomy of the abnormal periprosthesic tissue revealed locoregional recurrence.

Quantification of Extracellular Volume in CT in Neoadjuvant Chemotherapy in Breast Cancer: New Frontiers in Assessing the Cardiotoxicity of Anthracyclines and Trastuzumab

“…The main adjuvant and neoadjuvant chemotherapy regimens involve [ 5 ] the use of anthracyclines (AC), although recently new AC-free schemes are recommended for Her-2 positive BC [ 6 , 7 ] and in postmenopausal women presenting with a luminal-like lobular histotype where an endocrine therapy is preferred [ 8 , 9 ]. Indeed, AC and trastuzumab are among the most efficient antineoplastic drugs, particularly in triple negative BC (TNBC) and HER-2 positive BC, respectively, but they are burdened with an important cardiotoxicity (CTX) rate [ 10 , 11 ], especially doxorubicin (DOX) [ 12 ].…”

Socioeconomic Impact of OncotypeDX on Breast Cancer Treatment: Preliminary Results

“…Interestingly, while BHPQ reported intermediate values for questions regarding domains as sexuality, or daily activity, lower values were reported in domains regarding BC awareness and anxiety. Moreover, while LSQ-32 reported higher value in physical symptoms (1)(2)(3)(4), lower values were reported in domains assessing sickness impact, quality of everyday activities, socio-economic situation, quality of family relations, and quality of close friend relationship, demonstrating how chemotherapy sparing was associated with less side effects without affecting social and economic domains.…”

“…Breast cancer (BC) remains the most prevalent oncological diagnosis worldwide, with an annual incidence exceeding 2.3 million cases (1). During the past century, the approach to BC treatment has evolved from a singular surgical procedure to a multidisciplinary treatment strategy that takes into account both tumor and patient-related characteristics, including comorbidities and preferences (2)(3)(4).…”